España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Fate Therapeutics
FATE
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$1.27
0.02
1.60%
At close: -
$1.30
0.03
2.36%
After Hours: Jan 17, 6:37 PM EDT
Get Report
Comment
Fate Therapeutics (FATE) Forecast
News
Earnings
Fate Therapeutics (FATE) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Fate Therapeutics (NASDAQ:FATE) Stock
Fate Therapeutics Stock (NASDAQ: FATE)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, December 09, 2024
Fate Therapeutics shares are trading higher a...
Benzinga Newsdesk
Fate Therapeutics Unveils Phase 1 Data For FT...
Benzinga Newsdesk
Friday, November 29, 2024
Fate Therapeutics Announces Leadership Transi...
Benzinga Newsdesk
Wednesday, November 27, 2024
Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor
Tuesday, November 19, 2024
Needham Reiterates Hold on Fate Therapeutics
Benzinga Newsdesk
Monday, November 18, 2024
Fate Therapeutics Shares Halted On Circuit Br...
Benzinga Newsdesk
Fate Therapeutics shares are trading higher a...
Benzinga Newsdesk
Fate Therapeutics Presents 6-Month Follow-Up ...
Benzinga Newsdesk
Wednesday, November 13, 2024
Needham Reiterates Hold on Fate Therapeutics
Benzinga Newsdesk
Tuesday, November 12, 2024
Fate Therapeutics Q3 EPS $(0.40) Beats $(0.42...
Benzinga Newsdesk
Monday, November 11, 2024
Reported Saturday, Fate Therapeutics Showcase...
Benzinga Newsdesk
Thursday, August 22, 2024
HC Wainwright & Co. Reiterates Neutral on Fat...
Benzinga Newsdesk
Wednesday, August 14, 2024
Needham Reiterates Hold on Fate Therapeutics
Benzinga Newsdesk
Tuesday, August 13, 2024
Fate Therapeutics Q2 2024 Adj EPS $(0.33) Bea...
Benzinga Newsdesk
Tuesday, July 16, 2024
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor
Wednesday, June 26, 2024
Fate Therapeutics shares are trading lower ga...
Benzinga Newsdesk
Monday, June 17, 2024
Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts
Benzinga Insights
This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Avi Kapoor
Fate Therapeutics shares are trading higher a...
Benzinga Newsdesk
Piper Sandler Upgrades Fate Therapeutics to O...
Benzinga Newsdesk
Thursday, May 16, 2024
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
Avi Kapoor
HC Wainwright & Co. Maintains Neutral on Fate...
Benzinga Newsdesk
Friday, May 10, 2024
Canaccord Genuity Maintains Buy on Fate Thera...
Benzinga Newsdesk
BMO Capital Maintains Market Perform on Fate ...
Benzinga Newsdesk
Wedbush Maintains Neutral on Fate Therapeutic...
Benzinga Newsdesk
Piper Sandler Maintains Neutral on Fate Thera...
Benzinga Newsdesk
Thursday, May 09, 2024
Fate Therapeutics Q1 2024 GAAP EPS $(0.47), I...
Benzinga Newsdesk
Fate Therapeutics Treats First Lupus Patient ...
Benzinga Newsdesk
Monday, May 06, 2024
Forecasting The Future: 8 Analyst Projections For Fate Therapeutics
Benzinga Insights
Wedbush Reiterates Neutral on Fate Therapeuti...
Benzinga Newsdesk
Friday, May 03, 2024
Fate Therapeutics Announces Presentation Of F...
Benzinga Newsdesk
Tuesday, April 23, 2024
Wedbush Reiterates Neutral on Fate Therapeuti...
Benzinga Newsdesk
Monday, April 22, 2024
Fate Therapeutics To Present FT819 Proof-Of-C...
Benzinga Newsdesk
Thursday, April 11, 2024
Where Fate Therapeutics Stands With Analysts
Benzinga Insights
Needham Reiterates Hold on Fate Therapeutics
Benzinga Newsdesk
Wednesday, April 10, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
Thursday, March 28, 2024
B of A Securities Maintains Underperform on F...
Benzinga Newsdesk
Tuesday, March 19, 2024
Fate Therapeutics Announces Pricing Of $100M ...
Benzinga Newsdesk
Evaluating Fate Therapeutics: Insights From 5 Financial Analysts
Benzinga Insights
HC Wainwright & Co. Reiterates Neutral on Fat...
Benzinga Newsdesk
Tuesday, February 27, 2024
Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics
Benzinga Insights
Barclays Maintains Overweight on Fate Therape...
Benzinga Newsdesk
Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Avi Kapoor
Wedbush Maintains Neutral on Fate Therapeutic...
Benzinga Newsdesk
Oppenheimer Reiterates Perform on Fate Therap...
Benzinga Newsdesk
Monday, February 26, 2024
Recap: Fate Therapeutics Q4 Earnings
Benzinga Insights
Fate Therapeutics Q4 2023 GAAP EPS $(0.45) Be...
Benzinga Newsdesk
Earnings Scheduled For February 26, 2024
Benzinga Insights
Friday, February 23, 2024
A Preview Of Fate Therapeutics's Earnings
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
